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Ovarian cancer (OC) is the leading cause of death from gynecological malignancies. In spite of high
response rates to the standard front-line treatment for advanced disease with cytoreductive surgical deb-
ulking, followed by platinum/taxane-based chemotherapy, most patients eventually relapse developing
drug-resistant disease. Owing to the molecular heterogeneity, genetic instability and mutagenicity of
OC, increases in survival might be achieved by translating recent insights at the morpho-molecular levels
to individual therapeutic strategies. Several emerging treatments have been shown to be active in plat-
inum-sensitive (PS) recurrent OC (ROC), but an optimal strategy still has not been established. Based on
the recent results, it is likely that the introduction of novel non-platinum based chemotherapies and
molecular targeted therapies will have a major impact on the management of ROC. Some current strat-
egies are focused on the extension of platinum-free interval (PFI) in patients with PS, particularly in those
with partially PS disease. Apparently, the PFI extension by an effective non-platinum intervention, such
as trabectedin plus pegylated liposomal doxorubicin (PLD), may reduce cumulative platinum-induced
toxicities leading to longer survival after the reintroduction of subsequent platinum. The introduction
of novel therapies, such as the antiangiogenic monoclonal antibody bevacizumab, opens a new ﬁeld of
targeted therapies in this indication. In this review, we aim to outline the therapeutic potential of new
emerging approaches, particularly the role of non-platinum therapy with trabectedin in combination
with PLD in patients with PS ROC.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction ment paradigm for advanced epithelial OC has been maximalEpithelial carcinoma of the ovary is one of the most common
gynecologicmalignancies, with 50% of all cases occurring in women
over 65 years of age, and the ﬁfth most frequent cause of death by
cancer in women with approximately 125,000 deaths annually
worldwide [1]. Approximately 75% of women with ovarian cancer
(OC) present advanced stage of disease associated with poor
outcome. Over the past two decades the standard ﬁrst-line treat-cyto-reductive surgical debulking followed by platinum-based che-
motherapy with the prognosis of therapy closely related to the dis-
ease stage at diagnosis and the extent residual disease following
surgery [2]. Yet, while the median survival has been extended to
more than 4 years, overall survival (OS) has not changed over the
last 30 years.
In spite of high response rates to primary therapy (70–80%) [2–
5] only approximately 15% of women achieve cure [5]. The remain-
ing patients have drug-resistant disease or ultimately develop
incurable recurrent disease with an overall 5-year survival rate
lower than 50% [5,6]. Therefore, identiﬁcation of new drugs and
emerging treatment strategies for recurrent OC (ROC) represents
a clinical challenge.Treatment of recurrent platinum-sensitive ovarian cancer
ROC is not a curable disease; thus, the principal objective of sal-
vage treatments is to prolong survival in patients with platinum-
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patients with platinum-resistant (PR) disease, and alleviate
cancer-related symptoms. Re-treatment with platinum-based che-
motherapy is common practice in recurrent disease after relapse;
however, its effectiveness is highly correlated with platinum-free
interval (PFI) [7]. In 2010, the 4th Ovarian Cancer Consensus Con-
ference of the Gynecological Cancer InterGroup meeting held in
Vancouver established the deﬁnition of PFI as the interval from
the last date of platinum dose until documented progressive dis-
ease [8]. The initial bipolar empiric categorization of patients with
ROC on PR and PS patients, with a PFI of <6 months and
P6 months, respectively, did not sufﬁciently reﬂect the disease
prognosis since PFI is a continuous variable rather than one dichot-
omized at 6 months [9–11]. Therefore, it was agreed that the PFI
should be used to subcategorize patients into the following sub-
groups: platinum-refractory patients, with disease progression
while receiving last line of platinum-based therapy or within four
weeks of last platinum dose, PR (PFI <6 months), partially PS (PFI of
6–12 months) and fully PS (PFI >12 months) [8,12]. In addition to
PFI, duration of response to previous therapy, disease stage at time
of diagnosis, as well as patient’s tolerability, performance status
and preference of a particular treatment are the main criteria for
selecting therapies for ROC and also the most important prognostic
factors.
Patients with a fully PS relapse typically receive a salvage sec-
ond-line therapy based on rechallenge with platinum-containing
regimens with response rate ranging from 30% to 75% [13]. These
patients generally undergo a series of salvage treatments, with
each subsequent treatment associated with progressively shorter
PFI during disease remission. Markman et al. have reported that
the length of a prior response to platinum-based therapy seems
to be highly predictive of the upper limit of the response duration
of a subsequent platinum treatment, assuming the same or similar
drug/s are used for subsequent treatment [14]. Nevertheless, pa-
tients treated with a regimen consisting of platinum plus an agent
not administered during their prior treatment may have secondary
responses of longer duration than the previous one [14].
Among PS patients, those patients with partially PS (PPS) dis-
ease after primary platinum-based therapy, obtain substantially
lower response rate to platinum re-challenge (27–33%) [15]. Wo-
men with PPS disease represent 20–40% [16–20] of all patients,
for whom controversies and uncertainties still exist regarding the
best post-progression treatment. It has been proposed that PFI
extension through intercalation of a non-platinum therapy prior
to subsequent platinum rechallenge may increase the likelihood
of response of a later platinum re-treatment [21–27].
The treatment of ROC continues to evolve as new drugs with di-
verse mechanisms of action are introduced into the oncologist’s
armamentarium. The aim of this review is to identify the position
of emerging treatment strategies in the treatment algorithm for
ROC that ﬁts with the potential of those drugs. Moreover, since
there are women with ROC who could beneﬁt from a delay in plat-
inum re-treatment, who are not good candidates for platinum-
based therapy or this agent is not the best treatment option for
them, the selection of suitable patients who may largely beneﬁt
from non-platinum based therapy was also reviewed.
Genomic heterogeneity of ovarian cancer: toward patient-tailored
therapy
OC is a broad term for different heterogeneous cancers that are
derived from different, often non-ovarian tissues, resulting in the
different OC histotypes (i.e., mucinous, endometrioid, clear cell
and serous, high grade and low grade serous). Therefore, OC is a
misleading term for a series of genomically and etiologically
heterogenic diseases that often do not arise from ovarian tissueand simply share an anatomical location [6,28]. Given the com-
plexity of OC, the current single approach to treatment of OC as a
single disease has to move toward patient-tailored therapy based
on molecular and histotype-driven treatments. Recently, the Can-
cer Genome Atlas Research Network (TCGA) has described the
genomic and epigenomic abnormalities of 489 patients with ad-
vanced-stage, high-grade serous OC, with the aim to identify
molecular abnormalities that inﬂuence pathophysiology, out-
comes, and constitute therapeutic targets [29]. The integrated
analysis performed by TCGA has deﬁnitely demonstrated the low
mutation rate of high grade OC except for TP53 and BRCA1/2 genes
which were affected in 96% and 22% of OC, respectively, but with-
out a clear correlation between the expression and methylation
patterns of those genes and clinical outcomes. In contrast, exten-
sive focal and broad DNA losses and gains were seen through the
genome of OC with DNA deletions and ampliﬁcation in many
genes. Yet again, the patterns of methylation and gene expression
across the samples did not strongly correlate with clinical out-
comes. Therefore, it has been proposed that serous OC might not
be targeted with drugs, challenging if our understandings of the
plethora of genomic data will translate into clinically useful ap-
proaches (Birrer MJ, Genomic Analysis. Keynote Lecture, 9th Ad-
vanced Ovarian Cancer Symposium, Valencia, Spain. March 2013;
unpublished results). Regarding the association of BRCA1/2 muta-
tion with survival and sensitivity to platinum-based chemother-
apy, this and other genomic analyses of OC have conﬁrmed
improved OS and overall response rate (ORR) in patients with
germline BRCA mutations as compared non-carriers [29–32]. In-
deed, deﬁciencies of the homologous recombination pathway in
DNA repair can impair DNA cross-links repair introduced by plati-
num-based chemotherapy and result in higher survival rates due
to an improved response in BRCA-deﬁcient patients. Furthermore,
these homologous recombination defects sensitize tumors for tar-
geted therapies such as poly (ADP-ribose) polymerase (PARP)
inhibitors [33]. Therefore, in a variety of malignancies including
OC, enhanced expression of the DNA repair proteins, such as
BRCA1/2 and excision repair cross complementation group 1
(ERCC1), have correlated with resistance to both platinum and
PARP inhibitors [31,34–38]. Additionally, preclinical models and
ex-vivo results also demonstrated that the tumor microenviron-
ment has become an important focus of attention as an adjunct
to molecular therapeutics and chemotherapy in ovarian cancer.
Therefore, drugs ability to modulate the tumor microenvironment
might be largely responsible for the antitumor effects by decreas-
ing the factors potentially relevant for tumor growth, progression,
and metastatic spread [39].
Treatment endpoints in recurrent ovarian cancer
The optimal treatment for women with epithelial ROC is rapidly
evolving in parallel with our understanding of the pathways and
networks controlling cell signaling, proliferation, and cell death.
However, decision-making strategies for optimal treatment of
ROC are complex as many active cytotoxic drugs and an increasing
number of biological agents are becoming available [40]. This rep-
resents challenges in deﬁning the endpoints, optimal timing and
sequencing of most drugs or treatment regimen, such as mono-
therapy or in combination, particularly in the development of
new clinical trials. The most controversial issue of the ROC
treatment surrounds the lack of an OS advantage observed with
the number of investigational regimens and compounds, often
being associated with increased toxicity and no improvements in
patients QoL [17,18,20,41,42]. Therefore, the selection of clini-
cally-meaningful scientiﬁc objectives and standardized study end-
points is critical [7]. In contrast with ﬁrst-line therapy, where an
excellent correlation has been observed between progression-free
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clear. There was consensus that phase III trials for patients with
ROC should be large enough to detect clinically meaningful differ-
ences in both PFS and OS [7,8]. Though OS is an important end-
point, PFS is considered as the preferred primary endpoint for
phase III trials, since after disease progression patients often cross-
over to receive other study drug or different regimens. The extent
of clinically meaningful improvement in PFS as an early surrogate
for OS has been questioned since dissociations between PFS and OS
outcomes are commonly observed after trial completion, suggest-
ing that for many treatment settings an improvement in PFS does
not result in an improved OS [43,44]. The hazard of death is likely
to change after disease progression; thus, for clinical trials with a
PFS beneﬁt, lack of statistical signiﬁcance in OS does not necessar-
ily imply lack of improvement in survival, especially if post-pro-
gression survival is long (P12 months) [43,44]. It is important to
acknowledge that the impact of subsequent post-trial treatments
on a particular study’s outcome is likely to be unknown. Therefore,
it is still controversial what evidence of beneﬁt and how much of
improvement would be clinically meaningful for approval of a
new treatment or regimen in ROC [44–46]. Thus far, no data have
supported that routine treatment of women who only have asymp-
tomatic cancer antigen (CA)-125 increase may improve OS in the
recurrent setting [7]. Future research should also consider some
new endpoints such as clinical or symptom beneﬁt, which includes
health-related QoL, patient-reported outcomes regarding symp-
toms, and time without symptoms or toxicity.Chemotherapy use in platinum-sensitive disease
To date, just a few phase III randomized trials have demon-
strated a statistically signiﬁcant improvement in OS with an inves-
tigation drug/regimen in women with ROC. In some of those
studies no detailed or separate data for the PPS subgroup is re-
ported, essentially because until relatively recently the patients
with PPS recurrence were not recognized as a separate group. In
2003, the International Collaborative Ovarian Neoplasm 4 (ICON-
4) trial that evaluated 802 women with PS OC was the ﬁrst to show
that a combination of platinum and paclitaxel was more effective
than single-agent platinum compounds [16]. This study reported
that a combination of carboplatin and paclitaxel provided superior
PFS by a median of 3 months (12.0 vs. 9.0 months; p = 0.0004) and
OS by 5 months (29.0 vs. 24.0 months; p = 0.02) when compared
with treatment with carboplatin alone. In the study by Pﬁsterer
et al., a combination of gemcitabine and carboplatin in patients
with PS ROC was associated with a median improvement in PFS
of 2.8 months (8.6 vs. 5.8 months; p = 0.0031), but with greater
toxicity and no improvement in OS (18.0 vs. 17.3 months) and
QoL when compared with carboplatin alone [17]. The large phase
III CALYPSO trial, carried out in 976 patients with PS ROC, reported
that a combination of carboplatin and pegylated liposomal doxoru-
bicin (PLD) was associated with a 1.9- and 0.6-months improve-
ment in PFS in patients with PS (11.3 vs. 9.4; p = 0.005) and PPS
(9.4 vs. 8.8 months; p = 0.004) disease, respectively, compared with
the standard therapy of carboplatin and paclitaxel [18,42,47].
Although improvement in median PFS was modest, the combina-
tion of PLD and carboplatin was non-inferior and a less toxic alter-
native to the standard regimen of carboplatin and paclitaxel.
However, no statistically signiﬁcant difference was observed be-
tween arms in OS (30.7 vs. 33.0 months; p = 0.94), and in the PPS
subset, the ﬁnal survival data are not presented.
Current treatment options for patients with ROC are frequently
guided by safety considerations and convenience. Regardless of the
regimen, rechallenge with platinum-based chemotherapy is com-
monly limited by the risk of cumulative long-term toxicities.Overall, clinically signiﬁcant sequelae such as chemotherapy-in-
duced hypersensitivity reactions (20% of OC patients) [48],
neurotoxicity including residual neuropathy (23%) [49] and se-
vere cumulative myelosuppression [50] are commonly caused by
platinum-based chemotherapy. This issue should be carefully taken
into account before considering platinum re-treatment as the plati-
num-associated cumulative and irreversible toxicities may jeopar-
dize its long-term interventions on subsequent relapses [50].
Consideration of platinum-induced cumulative toxicity takes on
greater signiﬁcance as the number of salvage regimens increase, as
it could be given only to those patients ofwhom the toxicitieswould
be acceptable, underscoring the need for an efﬁcacious non-plati-
num regimen associated with an acceptable toxicity proﬁle.
Two randomized phase III studies have represented an impor-
tant step in the transition from platinum doublets to non-platinum
drugs, changing the paradigm in the treatment algorithm of pa-
tients with PS and PR ROC. Ten Bokkel Huinink et al. evaluated
topotecan and paclitaxel in relapsed disease and suggested that
topotecan had efﬁcacy at least equivalent to that of paclitaxel,
resulting in a higher response rate and median durations of re-
sponse in both PS and PR patients and signiﬁcantly longer time
to progression (23 vs. 14 weeks; p = 0.002) [41]. In the study by
Gordon et al. the efﬁcacy and safety of PLD and topotecan were
tested in 474 patients with ROC, 220 of whom had PS disease. They
reported that treatment with PLD signiﬁcantly prolonged survival
compared with topotecan (median OS: 14.4 vs. 13.7 months;
p = 0.05) [51,52]. Noteworthy, data analyzed in PS patients demon-
strated a far more pronounced statistically signiﬁcant beneﬁt of
PLD for PFS (median PFS: 6.7 vs. 5.4 months; p = 0.037) and OS
(median OS: 24.8 vs. 16.1 months; p = 0.017), with longer OS by a
median of 8.7 months. Further analysis demonstrated that the sur-
vival beneﬁt was more prominent in the PPS subgroup (n = 122;
hazard ratio [HR] = 1.58; p = 0.021) than in patients with a PFI of
>12 months (n = 97; HR = 1.15; p = 0.057) [15]. PLD and topotecan
have separately conﬁrmed to be feasible intervening non-platinum
agents for extending the PFI, resulting in acceptable toxicities and
response rates during platinum re-treatment in the setting of PS
disease [53,54]. These results lead to the regulatory approval of
PLD and topotecan by the Food and Drug Administration (FDA)
as single agents in the treatment of both PS and PR ROC. Moreover,
based on these studies the UK National Institute for Clinical Excel-
lence (NICE) recommends PLD as a single agent (or a platinum-tax-
ane combination) for the treatment of PPS ROC.
Trabectedin
Trabectedin (Yondelis

) is a tetrahydroisoquinoline alkaloid,
originally isolated from the marine tunicate Ecteinascidia turbinata
and currently produced synthetically. The trabectedin phase I pro-
gram documented responses in patients with ovarian carcinoma
[55]. Subsequently, three phase II studies reported promising activ-
ity of trabectedin as a single-agent, especially in patients with PS
disease, with a manageable and non-cumulative toxicity proﬁle
[56–58]. Trabectedin was the ﬁrst anticancer marine-derived drug
to be approved in the European Union in 2007 for the treatment of
patients with soft tissue sarcoma after failure of anthracyclines and
ifosfamide, or for those patients who are unsuitable to receive
these agents. Based on the results of a large phase III study OVA-
301, in 2009 the European Commission granted a marketing autho-
rization for the non-platinum combination of trabectedin with PLD
for the treatment of patients with PS ROC.
Trabectedin has a unique mechanism of action based on inter-
action with the minor groove of the DNA double helix, which trig-
gers a cascade of events that interfere with several transcription
factors, DNA binding proteins and DNA repair pathways, resulting
in G2-M cell cycle arrest and ultimately apoptosis (Fig. 1A) [59].
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tide excision repair (NER) and a deﬁcient homologous recombina-
tion repair (HRR) machinery [60]. Consequently, trabectedin shows
decreased activity (from 2- to 8-fold) in NER-deﬁcient cell lines,
while cells deﬁcient in HRR are approximately 100 times more sen-
sitive to the drug, indicating that trabectedin causes DNA double-
strand breaks [60–64].
Emerging evidence indicates that trabectedin has dual effects,
since in addition to induce direct growth inhibition, cell death
and differentiation of malignant cells it affects the tumor microen-
vironment by reducing the production of key inﬂammatory medi-
ators [39,59,65]. At therapeutic concentrations trabectedin has
selective anti-inﬂammatory and immunomodulatory properties
on monocytes and tumor associated macrophages (TAMs) and
inhibits the production of factors potentially relevant for tumor
growth, progression, and the inhibition of tumor-promoted angio-
genesis (Fig. 1B). In patients treated with trabectedin, a strong
dose-dependent and selective reduction of the production of pro-
tumoral inﬂammatory cytokines by monocytes, macrophages,
TAMs and freshly isolated ovarian tumor cells was observed
[39,65–67]. The markedly reduced production of those proinﬂam-
matory mediators, in particular CCL2, interleukin-6 (IL-6) and vas-
cular endothelial growth factor (VEGF), may underlie the strong
association between chronic inﬂammation and cancer progression.
Thus, trabectedin also targets inﬂammatory cells of the tumor
microenvironment reducing an angiogenic and pro-inﬂammatory
effect mediated by cytokines and leading to a delayed response
with a prolonged stabilization (i.e. tumor dormancy). Overall, tra-
bectedin is probably more than a cytotoxic drug, given that the
antitumor activity of trabectedin arises from a different combina-
tion of more than one mechanism, providing a consolidated thera-
peutic approach as a multitarget drug with far more multifaceted
activity than initially formulated. Through these mechanisms tra-
bectedin is likely to impact relevant biological pathways involved
in cancer, which may inﬂuence disease outcome.
The phase III OVA-301 study
The results from the randomized phase III OVA-301 trial, which
compared PLD (Doxil

/Caelyx

) with a combination of trabectedin
plus PLD, is gaining attention in the treatment of ROC, especially in
the subset of PPS relapse [19]. The pivotal OVA-301 trial (n = 672),
included both patients with PR (PFI <6 months) and PS disease (PFI
P6 months). The OVA-301 study differed from previous trials in
the same setting (e.g. CALYPSO andOCEAN trials) as it included only
the patients who were not expected to beneﬁt from or who were
ineligible for or who were not willing to receive re-treatment with
platinum-based chemotherapy. The eligible patients had received
one prior platinum-based chemotherapy and experienced either
persistence, recurrence or disease progression, and were required
to have measurable disease according to the Response EvaluationA.Trabectedin interacting at DNA level
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Double Strand Breaks
Transcription Modulation of
Specific Genes
Cell Cycle Arrest
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Fig. 1. Mechanism of acCriteria In Solid Tumors (RECIST) and an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status 62. The major exclusion cri-
teria were refractory disease and isolated rise in CA-125 without
documented radiological evidence of disease progression. The pri-
mary endpoint was PFS by blinded independent radiology review.
The results of OVA-301 in the whole population showed that tra-
bectedin plus PLD obtains signiﬁcant beneﬁts over PLD in terms of
PFS (median PFS: 7.3 months vs. 5.8 months; p = 0.019), ORR
(27.6% vs. 18.8%;p = 0.008) and a positive trend inOSover PLDalone.
The toxicity related to trabectedin plus PLDwas acceptable. Beneﬁts
appearedmoreevident in thePS subsetPFS (medianPFS:9.2 months
vs. 7.5 months; p = 0.0170) and even more pronounced in patients
with PPS disease with a PFI of 6–12 months PFS (median PFS:
7.4 months vs. 5.5 months; p = 0.0015) [19,27,68,69]. It was the ﬁrst
positive randomized phase III trial in ROC that included a non-plat-
inum and non-taxane combination. The ﬁnal analyses of patient-re-
ported outcomes have shown little or no decrement in patient-
reported functional status and symptoms in patients who received
trabectedin plus PLD as compared with PLD alone [70–72].
The study was designed to be sufﬁciently powered to consider
both PFS and OS results. Recently, the protocol-deﬁned analysis of
ﬁnal survival data in the overall population showed a 14% de-
crease in the risk of death for patients randomized to receive
the combination of trabectedin plus PLD (HR = 0.86; p = 0.0835;
unstratiﬁed log-rank test) [73]. The median OS was 22.2 months
for trabectedin plus PLD, and 18.9 months for the PLD arm (Ta-
ble 1). Despite study stratiﬁcation that resulted in well-balanced
arms in terms of the two platinum-sensitivity categories, i.e., PR
and PS, an unanticipated but signiﬁcant overall imbalance in
the PFI between the two arms favoring the PLD arm was observed
(mean PFI: trabectedin plus PLD = 10.6 months vs.
PLD = 13.3 months; p = 0.009) [73]. Because the log rank analysis
stratiﬁed by the dichotomous categorization into platinum resis-
tant (i.e., PFI <6 months) and platinum sensitive (i.e., PFI
P6 months) could not account for the imbalance in PFI between
both arms, a multivariate analysis based on the Cox regression
was performed following the statistical analysis plan of the study
to provide an appropriate and reliable estimate for treatment ef-
fect. The Cox proportional hazard model considered several pre-
speciﬁed prognostic factors as covariates, including PFI as a con-
tinuous variable. This analysis in the overall population resulted
in a relevant and signiﬁcant improvement in OS with a 18% de-
crease in the risk of death in patients treated with trabectedin
plus PLD compared with PLD (HR = 0.82; 22.6 vs. 19.4 months;
p = 0.0285) (Fig. 2A) ]. According to the log-rank Kaplan–Meier
test in patients with PS disease the treatment with trabectedin
plus PLD resulted in a 17% decrease in the risk of death as com-
pared with PLD alone (HR = 0.83; p = 0.1056) (Table 1) [74]. How-
ever, the results of the Cox regression showed that trabectedin
plus PLD resulted in a signiﬁcant 22% decrease in the risk of death
compared with the PLD arm (median OS: 28.4 vs. 24.1; HR = 0.78;B. Trabectedin effects on tumor microenvironment
Selective cytotoxicity on
tumor stroma macrophages
Inhibition of angiogenic
factor VEGF and reduction of
number of vessels
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Tumor Growth
Angiogenesis
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Metastases
Epithelial Mesenchimal
Transition (EMT)
INHIBITION
tion of trabectedin.
Table 1
Final analysis of overall survival (OVA-301 study).
Final overall survival analysis
Cut-off date: 12 November
2010
Median OS (months)
(95%CI)
Kaplan–Meier
unstratiﬁed
log-rank analysis
Trabectedin
plus PLD
PLD Hazard
ratioa
Median
(95% CI)
p
Value
All population 22.2 18.9 0.86 0.0835
(N = 672; 522 events/150
censored)
(19.3–25.0) (17.1–
21.5)
(0.72–
1.02)
Resistant (PFI <6 months) 14.2 12.4 0.92 0.5452
(N = 242; 206 events/36
censored)
(11.1–16.8) (10.6–
14.8)
(0.70–
1.21)
Sensitiveb (PFI P6 months) 27.0 24.1 0.83 0.1056
(N = 430; 316 events/114
censored)
(24.1–31.4) (20.9–
25.9)
(0.67–
1.04)
PPSc (PFI 6–12 months) 22.4 16.4 0.64 0.0027
(N = 214; 177 events/37
censored)
(20.3–27.7) (14.1–
19.4)
(0.47–
0.86)
Very sensitivec (PFI
P12 months)
36.5 31.7 0.83 0.2750
(N = 217; 140 events/77
censored)
(26.3–42.3) (25.9–
39.7)
(0.59–
1.16)
a Over PLD alone.
b Sensitive population: PFI P6 months as determined at randomization by the
study investigators.
c PFI categories are based on PFI data calculated from case report form. CI, con-
ﬁdence interval; PFI, platinum-free interval; PLD, pegylated liposomal doxorubicin;
PPS, partially platinum-sensitive; OS, overall survival.
370 A. Poveda et al. / Cancer Treatment Reviews 40 (2014) 366–375p = 0.0319) (Fig. 2B). In patients with PPS disease, the PFI imbal-
ance was less pronounced between treatment arms and not sta-
tistically signiﬁcant. Therefore, both the results of a log-rank
Kaplan–Meier test (HR = 0.64; 22.4 months vs. 16.4 months;
p = 0.0027), with an outstanding 36% decrease in the risk of death
(Table 1), and the results of a Cox regression analysis, with a 35%
decrease in the risk of death (HR = 0.65; 21.0 vs.
17.2 months;p = 0.0056) (Fig. 2C), showed a signiﬁcant improve-
ment in OS in patients treated with trabectedin plus PLD over
PLD alone. Finally, the median OS in very sensitive patients with
a PFI >12 months with trabectedin plus PLD (36.5 months) was in
the range of that obtained with platinum combinations (Table 1).
There results in combination with a manageable safety proﬁle of
trabectedin plus PLD makes this combination a valuable alterna-
tive for PS patients with ROC.A All patients; n=672 B Platinum-sensitive pa
(PFI 6 months); n=4
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Fig. 2. Final analysis of overall survival in all randomized patients and patient subgrou
hazard model. HR and p value for treatment comparison (over PLD alone) based on Cox
status, PFI as a continuous variable, race, baseline CA-125, age, baseline liver/lungs involv
Group; HR, hazard ratio; PFI, platinum-free interval; PLD, pegylated liposomal doxorubiSubsequent treatments following OVA-301
Additional beneﬁts with trabectedin plus PLD in 214 patients
(32%) with PPS disease were observed upon administration of sub-
sequent therapies. Previously the results of a post hoc exploratory
analysis provided a detailed assessment of subsequent therapies
and reported no major differences in post-progression therapies
between arms [27,69]. Subsequent platinum-based treatment as
any further line of chemotherapy was given to 121 patients with
PPS disease. In this patients subset, trabectedin plus PLD induced
a 6-months longer median OS with a signiﬁcant 36% decrease in
the risk of death compared with PLD alone (22.4 vs. 16.4 months;
HR = 0.64; p = 0.0027), most likely as a result of an extension of
the PFI (9.8 vs. 7.9 months; HR = 0.64; p = 0.0167) coupled with
longer survival after the start of subsequent platinum-based
chemotherapy (13.3 vs. 9.8 months; HR = 0.63; p = 0.0357) [69].
Differences were especially larger in patients who received plat-
inum as ﬁrst subsequent third-line therapy after discontinuation of
OVA-301 (n = 94). Trabectedin plus PLD treatment resulted in an
exceptional reduction of 42% in the risk of death compared with
PLD (HR = 0.58; p = 0.0153) (Fig. 3). Median OS for trabectedin plus
PLD was 27.7 months and 18.7 months for PLD alone with a nota-
ble improvement of 9-month in median OS. In this subpopulation,
patients treated with trabectedin plus PLD received subsequent
platinum later than those treated with PLD alone, with a median
prolongation of the PFI of 4 months (11.5 vs. 7.5 months;
HR = 0.61; p = 0.0203) [27]. The delay in subsequent platinum
treatment was largely translated into an OS extension from ﬁrst
platinum by a median of 8.9 months (18.8 vs. 9.9 months;
HR = 0.64; p = 0.0513) with respect to PLD alone, suggesting that
extension in the PFI may improve the response to subsequent rein-
troduction of platinum [27].
OVA-301: current evidences
Overall, in OVA-301 beneﬁts in PFS and OS were demonstrated
in the PS subset of patients, and especially in patients with PPS dis-
ease, conﬁrming the importance of the PFI as a key predictor of
outcome in ROC: a longer PFI predicts a longer OS [73–75]. OC be-
haves as a chronic disease beneﬁting from multiple lines of plati-
num-based therapy. However, a maximum of three lines of
subsequent relapse treatment seems to be beneﬁcial for patients
with ROC [76]. In contrast, the treatment with trabectedin as a sin-
gle-agent evidenced no differences in response rate according to
prior chemotherapy, given that patients with >1 line of previous
chemotherapy (range: 2–4 lines) had response rates comparabletients 
30 
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Fig. 3. Final analysis of overall survival in patients with partially platinum-sensitive disease (PFI of 6–12 months) from OVA-301 receiving platinum as ﬁrst subsequent third-
line chemotherapy (unstratiﬁed log-rank test according to Kaplan–Meier analysis). C, number of censored patients; CI, conﬁdence interval; PFI, platinum-free interval; HR,
hazard ratio; PLD, pegylated liposomal doxorubicin; OS, overall survival; T, trabectedin.
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chemotherapy [58,77]. Moreover, in PS patients who did not
achieve a complete response after ﬁrst-line platinum-based treat-
ment before OVA-301 an enhanced beneﬁt with trabectedin plus
PLD in terms of PFS and response rate was also observed [78].
Rechallenge with platinum and taxanes drugs has been limited
by the risk of residual toxicity or hypersensitivity reactions [48–
50]. Therefore, the PFI extension by trabectedin plus PLD may rep-
resent an additional beneﬁt for patients with PS disease by giving
them some extra time to recover from toxic effects of their prior
platinum-based therapy, and thus allowing future treatment op-
tions. The data from OVA-301 additionally support that PFI can
be prolonged by an effective non-platinum intervention between
platinum regimens resulting both in survival advantage when re-
introducing the subsequent platinum and recovery from previous
platinum-induced toxic effects [23–25].
In contrast to results observed with many other drugs/regi-
mens, the enhanced beneﬁt in PFS seen in all patient populations
treated with trabectedin plus PLD has translated into survival ben-
eﬁt, suggesting the role of PFS as an early surrogate for OS in ROC.
Particularly exciting results were those observed in patients with
PPS disease, where a 35% risk reduction of disease progression or
death was translated into a 36% reduction in the risk of death
and a 6.0-month improvement in median OS favoring the trabect-
edin plus PLD combination [68,73]. The exploratory analyses have
previously underlined that the superiority of trabectedin plus PLD
over single-agent PLD cannot be explained by the differences in the
extent or nature of subsequent therapies, which were similar be-
tween the two treatment arms [27]. Instead, the longer survival
with subsequent platinum is more likely to be due to a longer
PFI leading to a signiﬁcant delay of the rechallenge with subse-
quent platinum therapy and ultimately to longer survival.Targeted therapies in the treatment of ROC
Although different ‘‘targeted therapeutic approaches’’ are cur-
rently being explored, with the important exception of antiangio-genic agents, such as bevacizumab, cediranib and pazopanib, and
PARP inhibitor, olaparib, limited biological and clinical activity
have been demonstrated in treating ROC.Bevacizumab
Bevacizumab (Avastin

), a humanized recombinant monoclo-
nal VEGF-A-neutralizing antibody, has been the most studied
antiangiogenic agent. The results of phase II feasibility studies
of bevacizumab as monotherapy or in combination supported
the addition of bevacizumab to platinum-based regimens and
provided the rationale for designing phase III trials for testing
bevacizumab both as ﬁrst- and second-line treatment of pa-
tients with OC [79–82]. To date, two randomized phase III trials
have evaluated the addition of bevacizumab to front-line che-
motherapy and as maintenance therapy for OC (GOG-0218
and ICON-7/AGO-OVAR-11) [83,84]. While both trials met their
primary endpoints (superior PFS as compared to standard che-
motherapy), the advantage appeared to be derived primarily
from the maintenance therapy, with convergence of the PFS
curves shortly after bevacizumab treatment discontinuation,
with no signiﬁcant difference in OS and QoL scores across
treatment groups. Only among the women at high-risk for
progression subgroup (FIGO stage IV) enrolled in the ICON-7/
AGO-OVAR-11 study, statistical signiﬁcance in favor of the
bevacizumab arm was reached for median OS (bevacizumab
arm: 36.6 months vs. standard-therapy arm: 28.8 months;
HR = 0.64; p = 0.002) [86]. Nevertheless, surprisingly no such
OS differences were observed in GOG 0218, in which only
high-risk patients were enrolled. The hypothesis, whether the
beneﬁt in term of PFS after the addition of bevacizumab to
front-line chemotherapy may further modulates the clinical
outcome after the start of subsequent therapies, still remains
speculative. Recently, a cost-effectiveness analysis of bevacizumab
based on the results of GOG-0218 indicated that the addition of
bevacizumab as maintenance therapy to standard chemotherapy
is not cost-effective [85].
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In ROC, two phase III studies with bevacizumab (15 mg/kg; gi-
ven every 3 weeks) concomitantly administered with chemother-
apy and pursued in maintenance until progression have been
launched in sensitive relapse: GOG-213 and OCEANS [20,86]. The
non-registration GOG-213 trial exploring the addition of bev-
acizumab to carboplatin plus paclitaxel chemotherapy in patients
with PS disease is still in progress.
In the phase III registration-quality OCEANS protocol 484 wo-
men with PS ROC (PFI P6 months after front-line platinum-based
therapy) were randomly assigned to receive 6–10 cycles of carbo-
platin (AUC 4) plus gemcitabine (1 g/m2) chemotherapy with either
bevacizumab (15 mg/kg) or placebo followed by bevacizumab or
placebo, respectively, as maintenance therapy until disease pro-
gression [20]. All patients were required to have measurable dis-
ease according to RECIST v.1.0 and an ECOG performance status of
0 or 1. The patients were stratiﬁed by time from last platinum treat-
ment to recurrence (PFI 6–12 vs. >12 months) and secondary cyto-
reductive surgery for ROC (yes vs. no). The bevacizumab arm
signiﬁcantly increased PFS compared with chemotherapy alone
with the median PFS of 12.4 months for bevacizumab arm vs.
8.4 months for chemotherapy group (HR = 0.484; p < 0.0001). Note-
worthy, median PFS in the chemotherapy arm (8.4 months) was al-
most identical to median PFS (8.6 months) observed in the
carboplatin-gemcitabine arm in AGO OVAR trial [17]. As for ICON-
7, the addition of bevacizumab signiﬁcantly increased the ORR by
20% (78.5% vs. 57.4%; p < 0.0001) and the median duration of re-
sponse (10.4 vs. 7.4 months; HR = 0.534; 95% CI: 0.408–0.698).
Although the OS data from OCEANS are not sufﬁciently mature to
draw clear conclusions, the results of the third interim analysis,
based on 286 deaths (59% of patients), showed an unfavorable trend
in survival in the bevacizumab arm comparedwith results obtained
with the chemotherapy control group [87]. With a median follow-
up of 42 months, median OS was 33.7 months in the chemotherapy
arm and 33.4 months in the bevacizumab arm (HR: 0.96; CI 95%:
0.760–1.214; log-rank p = 0.736). The third interim analysis also
evidenced that 89.3% (control arm) and 85.5% (bevacizumab arm)
of patients received subsequent anticancer therapy, including bev-
acizumab as a single agent in 39.4% (control arm) and 22.2% (bev-
acizumab arm) of patients. Unfortunately, in OCEANS no data
regarding patients’ QoL were collected. Grade P3 hypertension
(0.4% vs. 17.4%) and proteinuria (0.9% vs. 8.5%), and non-central ner-
vous system bleeding of any grade (0.9% vs. 5.7%) occurred more
frequently in the bevacizumab arm, but no more than expected
according to data from other studies. Based on the recently reported
results of OCEANS study, in September 2012 the European Commis-
sion granted marketing authorization for bevacizumab in combina-
tion with carboplatin and gemcitabine as a treatment for women
with ﬁrst recurrence of PS OC who have not received prior therapy
with bevacizumab or other VEGF inhibitors or VEGF receptor–tar-
geted agents.
Although there is evidence that bevacizumab prolongs disease
control in PS ROC, the improvement in PFS in any of phase III trials
with bevacizumab did not translate into an OS advantage. Cross-
over, post-progression survival and development of resistance are
probably reasons to explain the lack of OS beneﬁt as well as the
limited power of the sample. Several groups have evaluated the
dynamics of tumor re-growth and survival, particularly regarding
the appearance of a more aggressive and invasive disease following
discontinuation of bevacizumab treatment. They demonstrated
that radiographic regression of different tumor types can be sus-
tained under continuous bevacizumab application; however, after
withdrawal of bevacizumab a rapid tumor re-growth and ‘‘re-
bound’’ phenomenon with accelerated clinical decline was ob-
served [88–90]. Additional results, expected to arrive in 2013,and future trials will provide important answers regarding the ex-
act place of bevacizumab therapy in the recurrent setting, particu-
larly regarding its optimal dose, treatment duration, and regimen.
Furthermore, the optimal patients’ selection to be treated with
bevacizumab based on predictive biomarkers as well as factors
including the drug’s cost and potentially serious side effects with
bevacizumab require serious consideration.
Other biological drugs
Other promising agents in various phases of investigation
include multitargeted antiangiogenic tyrosine kinase inhibitors,
such as cediranib and pazopanib, and the oral PARP inhibitor,
olaparib.
Cediranib (AZD2171) is a potent oral tyrosine kinase inhibitor
of all three VEGF receptors. Currently ICON-6, the three-stage,
double-blind, placebo-controlled study, is the most advanced
randomized phase III study that has evaluated cediranib plus
chemotherapy in women with PS recurrence in ﬁrst relapse
[91]. Patients were randomized (2:3:3) to receive either six
cycles of standard chemotherapy (paclitaxel 175 mg/m2 and
carboplatin AUC 5–6) concurrent with placebo; standard
chemotherapy with cediranib-initiation (20 mg/day) treatment
followed by placebo, or the same cediranib-initiation treatment
followed by cediranib maintenance for 18months or until disease
progression. The results of the blinded ﬁrst-stage analysis
performed in 60 patients conﬁrmed the safety of carboplatin
and paclitaxel in combination with cediranib and recommended
to expand ICON-6 to next stage [91].
Pazopanib (GW786034) is an oral antiangiogenic tyrosine ki-
nase inhibitor associated with the VEGF, PDGF and KIT recep-
tors. The results from the AGO-OVAR-16 study recently
announced that pazopanib as maintenance therapy in women
with advanced OC who have not progressed after front-line che-
motherapy signiﬁcantly extends time without recurrence (med-
ian PFS: 17.9 vs. 12.3 months; HR: 0.77; 95% CI: 0.64–0.91;
p = 0.0021). The OS data (20% maturity) from this study are
not mature [92].
Olaparib (AZD2281) is a novel and the most studied orally
active PARP inhibitor, which has shown antitumor activity in
patients with ROC with BRCA germline mutations, a phenotype
referred to as ‘‘BRCAness’’, and in lower extent in BRCAness-
negative patients with a dysfunction of the homologous recombi-
nation DNA repair mechanism [93,94]. In a randomized phase II
proof-of-concept trial the encouraging rate of responses have been
observed in both PS (38%) and PR (30%) BRCA mutation carriers
treated with olaparib 400 mg twice daily [95]. The results of phase
II randomized, placebo-controlled study with olaparib, given as
maintenance in PS ROC, showed that olaparib was associated with
a signiﬁcantly longer PFS (8.4 months) than in the placebo group
(4.8 months), irrespective of BRCA status [96]. However, the
interim analysis of this study evidenced that longer PFS did not
translate into an improvement in OS. Recently, the results of a
preplanned subgroup analysis from this study in 136 (51%)
patients with a proved BRCA mutation (BRCAm) status conﬁrmed
that olaparib maintenance therapy prolonged PFS compared with
placebo (median PFS: 11.2 vs. 4.3 months; HR: 0.19; 95% CI:
0.11–0.31; p < 0.0001). A second interim analysis of OS (58%
maturity) fail again to demonstrate a statistical signiﬁcant
difference between the two arms (median OS: 29.8 vs.
27.8 months; HR: 0.88; 95% CI: 0.64–1.21) [97]. Finally, the
comparative assessment of olaparib (400 and 200 mg twice
daily) and PLD (50 mg/m2) in patients with BRCA 1 or BRCA2
mutations and ROC in a phase II randomized study resulted in
no statistically signiﬁcant differences in PFS and ORR between
both treatments [98].
A. Poveda et al. / Cancer Treatment Reviews 40 (2014) 366–375 373Concluding remarks
A number of questions remain regarding the optimal treatment
of PS ROC. Although platinum-based drugs are regularly used in
patients with PS disease, uncertainties abound in the treatment
of women with PPS relapse and women unsuited for platinum
rechallenge. Considering the histological heterogeneity, distinct
genetic abnormalities and treatment responses of ovarian cancers,
the individualized patient selection is essential for the successful
targeted treatment of speciﬁc groups of patients. Moreover, an
effective consolidation or maintenance treatment with new drugs
with acceptable non-cumulative toxicity to reduce the risk of
recurrence after a clinical response and improve survival probably
will have a great impact in ROC.
The responses seen with bevacizumab combined with chemo-
therapy in ROC evoke potential for future therapeutic strategies.
Yet, several strategic questions need to be addressed before bev-
acizumab and other angiogenesis inhibitors become a part of stan-
dard therapy: the optimal use of these agents in ﬁrst- or second-
line regimens; should it be given as single-agent or in combination,
in which dose/schedule and for how long, throughout treatment or
as a maintenance therapy only; how to avoid/overcome the ac-
quired resistant to those agents, and, ﬁnally, which are the best
biomarkers for patient selection to predict tolerability and re-
sponse? Regarding the latter question, for bevacizumab a range
of predictive biomarkers have been proposed but none have
proved to be robust [99]. The development of predictive biomark-
ers is an urgent and crucial step for selecting patients likely to de-
rive beneﬁt from these therapies, which will ultimately help us to
move from an organ-speciﬁc approach towards a target and per-
sonalized treatment strategy of OC. In summary, based on the ab-
sence of data indicating bevacizumab improves OS when delivered
with platinum-based chemotherapy in the setting of PS recurrent
disease, a far stronger clinical and cost-effectiveness argument
has to be made to support the administration of this novel drug.
The OVA-301 study demonstrated the superiority of trabectedin
plus PLD over PLD alone in the overall population of patients, with
striking differences in outcomes in patients with PS disease and the
subset of patients with PFI 6–12 months who achieved a signiﬁcant
improvement of 6-months in median OS. Although deﬁnitive com-
parisons of trabectedin plus PLD to cytotoxic combinations are still
lacking, the clinical activity of this combination has documented
comparable activity to platinum combinations among PS patients.
The results from OVA-301 have called into question the paradigm
of platinum plus/minus taxane as mainstay treatment for patients
with PS ROC, since those results support the hypothesis that the
‘‘artiﬁcial’’ prolongation of the PFI by intercalation with an effective
non-platinum regimen improves the outcome with subsequent
platinum treatment ultimately leading to longer survival
[19,27,68,69]. In addition, extending the PFI would decrease cumu-
lative long-term toxicities caused by platinum-based chemother-
apy that increase with the number of treatments and can
preclude their use on subsequent relapses, and provide some extra
time for patients to recover from platinum-induced toxic effects
allowing future treatment options. Therefore, the combination of
trabectedin plus PLD now may represent an acceptable non-plati-
num/non-taxane alternative in treating patients with PS relapse,
particularly for patients with PPS disease who can beneﬁt from a
delay in platinum re-treatment, patients with PS relapse suffering
from platinum-induced toxicities or hypersensitivity or for pa-
tients who had received more than one platinum-based chemo-
therapy. Nevertheless, in the absence of randomized trials it is
impossible to demonstrate the superiority of trabectedin plus
PLD over standard platinum-based chemotherapy (±bevacizumab)
in the setting of PS recurrent disease. Therefore, furtherrandomized trials are needed to conﬁrm the hypothesis of the
‘‘PFI extension strategy’’ with this combination. Notably, the on-
going academic phase III INOVATYON (refers to: INternational
OVArian cancer patients Treated with YONdelis) trial is aimed to
demonstrate that the combination of trabectedin plus PLD pro-
longs OS over carboplatin plus PLD (the regimen evaluated in the
CALYPSO trial) in patients with PPS ROC.
Although we are currently experiencing a shift toward molecu-
lar targeted anticancer treatments, chemotherapies either alone or
in combination with other diverse biological treatment will con-
tinue to be a mainstay of treatment for patients with ROC. Treat-
ment of patients with ROC will possibly beneﬁt most from the
careful alignment of new cytotoxic chemotherapies and regiments,
new trial designs and the addition of therapies targeting critical
pathways responsible for tumor progression.
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